Glomerulonefritis lúpica y otras glomerulonefritis autoinmunes
Resumen
La glomerulonefritis es un término empleado para expresar la proliferación e inflamación endocapilar del glomérulo renal, que clínicamente puede manifestarse de numerosas formas e incluso permanecer asintomática. En su etiología se encuentran múltiples mecanismos, como la participación de microorganismos y parásitos, aunque es destacable el mecanismo autoinmune en el que se identifican varios componentes del sistema inmune, entre ellos el sistema del complemento. Un ejemplo de este último mecanismo es la glomerulonefritis secundaria al Lupus Eritematoso Sistémico (LES), que ha sido objeto de investigación en los últimos años, y en la que se han hecho importantes avances en cuanto al descubrimiento de nuevas moléculas implicadas en el proceso etiopatogénico. Esto ha conseguido abrir una puerta a nuevas terapias que reduzcan la mortalidad y mejoren la calidad de vida. Se ha revisado la fisiopatología, clínica, diagnóstico, pronóstico y tratamientos, incluyendo los emergentes, en cuanto a glomerulonefritis haciendo hincapié en la glomerulonefritis lúpica y otras glomerulonefritis de mecanismo igualmente.Citas
León Castro A, Huertas JF, Hurtado JS. Glomerulonefritis aguda con énfasis en compromiso rápidamente progresivo. Colomb Médica 2011; 42: 536-48.
Couser, W. G. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23: 381-399.
Pirkle JL, Freedman BI, Fogo, AB. Immune Complex Disease with a Lupus-like Pattern of Deposition in an Antinuclear Antibody-Negative Patient. Am J Kidney Dis 2013; 62: 159-164.
Fernández Castillo R, Fernández Gallegos R, Cañadas De la Fuente GA, González Jiménez E, El Hamed H. Pioderma gangrenoso en un paciente con insuficiencia renal crónica sobre fístula arteriovenosa secundaria a granulomatosis de Wegener. Estudio de un caso. Rev Nefrol Dial Tras 2012; 32: 222.
Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 2013; 84: 4-44.
Cheng Q, Mumtaz IM, Khodadadi L, Radbruch A, Hoyer BF, Hiepe F. Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 2013; 72: 2011-17.
Argote E, Castro AL, Otero LM. Glomerulonefritis. Colomb Medica 2011; 42: 536-548.
Kowalewska, J. Pathology of recurrent diseases in kidney allografts: membranous nephropathy and focal segmental glomerulosclerosis. Curr Opin Organ Transplant 2013; 18: 313-18.
Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in Nephrotic Syndrome. Semin Thromb Hemost 2013; 39: 469-76.
Namdev S, Krishnamurthy S, Biswal N, Jagadisan B. Pericardial Tamponade in Nephrotic Syndrome: An Uncommon Complication. Indian J Pediatr 2013; 80: 598-600.
Moreno JA, Martin-Cleary C, Gutierrez E, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transpl 2012; 27: 28-U523.
Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens. 2011; 20: 271-77.
Marovelli L, Larzábal I, Zopi E, Carreño CA, Winkel M, Miserendino D. Microangiopatía trombótica atrombocitopénica: un diagnóstico no realizado con los criterios actuales. Rev Nefrol Dial Traspl 2012; 32: 47-50.
Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pedriatr Nephrol 2008; 23: 1957-72.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274.
Spaulding AR, Salgado-Pabon W, Kohler PL, Horswill AR, Leung DYM, Schlievert PM. Staphylococcal and Streptococcal Superantigen Exotoxins. Clin Microbiol Rev 2013; 26: 422-47.
Samuels JA, Strippoli GFM, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database of Systematic Review 2003; 4: CD003965.
Goch D, Verna M. Nefropatía lúpica: Revisión. Revista de Posgrado de la VIa Cátedra de Medicina 2003; 125: 7-9.
Ruiz-Irastorza G, Espinosa G, Frutos MA, et al. Diagnóstico y tratamiento de la nefritis lúpica. Documento de consenso del Grupo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI) y de la Sociedad Española de Nefrología (S.E.N.). Nefrología 2012; 32: 1-35.
Chafin CB, Reilly CM. MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis. Clin Dev Inmunol 2013.
Nisihara RM , Magrini F, Mocelin V , Messias-Reason IJ. Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum Immunol 2013; 74: 907-10.
Polanco Flores NA, Soto Abraham MV, Rodríguez Castellanos FE. Utilidad de la Biopsia Renal Seriada en Nefropatía Lúpica. Rev Nefrol Dial Tras 2013; 33: 16-24.
Rodríguez Ospino HE, Gonzalez Paganti L, Lobo J. Nefropatía Mesangial Primaria por IgA e IgM. Rev Nefrol Dial Tras 2013; 33: 75-84.
Ruggiero B, Vivarelli M, Gianviti A, Benetti E, Peruzzi L, Barbano G, et al. Lupus Neprhitis in Children and Adolescents: Results of the Italian. Nephrol Dial Transpl 2013; 28: 1487-96.
Frieri M, Samih MA, Dzhindzhikhashvili M, Liu H, Balsam L, Rubinstein S. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol 2012; 25: 1041-46.
Dolff S, Abdulahad WH, Arends S, et al. Urinary CD8(+) T-cell counts driscriminate between active and inactive lupus nephritis. Arthritis Res Ther 2013; 15: R36.
Golbus J, McCune WJ. Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin N Am 1994; 20: 213-42.
Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transpl 2012; 27: 3248-54.
Ribeiro FM, Fabris CL, Bendet I, Lugon JR. Survival of lupus patients on dialysis: a Brazilian cohort. Rheumatology 2013; 52: 494-500.
Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int 2007; 71: 491–95.
Morris HK, Canetta PA, Appel GB. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transpl 2013; 28: 1371-76.
Richey M. The management of lupus nephritis. Nurs Pract 2014; 39: 1-6.
Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 2011; 7: 697-705.
Ooi JD, Chang J, O’Sullivan KM, et al. The HLADRB1* 15:01- Restricted Goodpasture`s T Cell Epitope Induces GN. J Am Soc Nephrol 2013; 24: 419-431.
Ohlsson S, Herlitz H, Selga D, et al. Circulating Anti-Glomerular Basement Membrane Antibodies With Predominance of Subclass IgG4 and False-Negative Immunoassay Test Results in Anti-Glomerular Basement Membrane Disease. Am J Kidney Dis 2014; 63: 289-93.
Mori M, Nwaogwugwu U, Akers GR, McGill RL. Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis. Clin Nephrol 2013; 80: 67-71.
Reynolds J, Norgan VA, Bhambra U, Smith J, Cook HT, Pusey CD. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2002; 13: 359-69.
Kalantari S, Rutishauser D, Samavat S, Nafar M, Mahmudieh L, Rezaei-Tavirani M. Urinary Prognostic Biomarkers and Classification of IgA Nephropathy by High Resolution Mass Spectrometry Coupled with Liquid Chromatography. Plos One 2013; 8(12): e80830.
Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikoshi S, et al. Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nephrol Dial Transpl 2013; 28: 320-26.
Roberts ISD. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hyper 2013; 22: 281-86.
Woo KT, Lau YK, Choong HL, et al. Genomics and disease progression in IgA nephritis. Ann Acad Med Singap 2013; 42: 674-80.
Pozzi C, Andrulli S, Pani A, et al. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol 2013; 26: 86-93.
Tang SCW, Leung JCK, Lai KN. Immunomodulatory agents against IgA Nephropathy. Adv Otorhinolaryngol 2011; 72: 45-9.
Cheng J, Zhang X, Tian J, Li Q, Chen J. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 2012; 66: 917-923.
Schonermarck U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. Nat Rev Nephrol 2014; 10: 25-36.
Harabuchi Y, Kishibe K, Komabayashi Y. Clinical manifestations of granulomatosis with polyangiitis (Wegener’s granulomatosis) in the upper respiratory tract seen by otolaryngologists in Japan. Clin Exp Nephrol 2013;17: 663-66.
Siomou E, Tramma D, Bowen C, Milford DV. ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol 2012; 27: 1911-20.
Thai LH, Charles P, Resche-Rigon M, Desseaux K, Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 2014; 13: 313-18.
Malina M, Schaefer B, Waldherr R, Wuhl E, Schaefer F, Schmitt CP. Late recovery of renal function by rituximab in a patient with Wegener’s granulomatosis. Pediatr Nephrol 2013; 28: 511-14.
Siomou E, Tramma D, Bowen C, Milford DV. ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol 2012; 27: 1911-20.
